You are adding an alert for:
Twelve months outcomes of Intravitreal aflibercept for neovascular age-related macular degeneration. Fixed versus as needed dosing.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: